Author:
Kato Terufumi,Masuda Noriyuki,Nakanishi Yoichi,Takahashi Masashi,Hida Toyoaki,Sakai Hiroshi,Atagi Shinji,Fujita Shiro,Tanaka Hiroshi,Takeda Koji,Satouchi Miyako,Namba Yoshinobu,Tamura Tomohide
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference11 articles.
1. Current status of DILD in molecular targeted therapies;Saito;Int. J. Clin. Oncol.,2012
2. Safety activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N. Engl. J. Med.,2012
3. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015
4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015
5. ONO Pharmaceutical. A Phase 2 study of ONO-4538 in patients with stage IIIB/IV or recurrent squamous NSCLC [JapicCTI-132072]. Available at URL: http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132072 (Accessed 21 July 2016).